乙肝相关肝细胞癌患者抗病毒治疗利用情况:美国全国真实世界研究
基于美国Optum Clinformatics行政理赔数据库(2003-2021)纳入2129例乙肝相关肝细胞癌患者,仅37%接受口服抗病毒治疗(OAV),2010年后治疗率较之前提高(40.5% vs 26.3%,P<.001)。女性、非亚裔、无肝硬化及无消化科/肝病科或感染科专科诊疗者治疗率显著更低;诊断时或之前启动OAV与生存改善独立相关(aHR 0.84,95%CI 0.72-0.99,P=.037)。
要点
- 乙肝相关肝细胞癌患者中仅约1/3接受口服抗病毒治疗。
- 亚裔、男性、有代偿期肝硬化及专科诊疗者更可能接受抗病毒治疗。
- 诊断时或之前启动抗病毒治疗与生存改善独立相关(aHR 0.84)。
核心结论
- 在享有医疗保险的乙肝相关肝细胞癌患者中,仅1/3接受了口服抗病毒治疗。
- 需继续努力改善乙肝口服抗病毒治疗,尤其是女性、非亚裔、无肝硬化或未就诊专科的患者。
研究设计与样本
- 研究基于去标识化行政理赔数据库Optum Clinformatics(2003-2021)识别乙肝相关肝细胞癌患者。
- 共纳入2129例患者:71%男性,平均年龄62.7±12.5岁,40%亚裔,72%肝硬化,37%接受口服抗病毒治疗。
主要发现
- 口服抗病毒治疗率随时间改善:2010年后为40.5%,早于2010年为26.3%(P<.001)。
- 女性、非亚裔、无肝硬化及无消化科/肝病科或感染科专科诊疗的患者治疗率显著更低(P<.0001)。
- 与治疗相关的因素包括亚裔(aOR 3.6,95%CI 2.8-4.5,P<.001)、男性(aOR 1.6,95%CI 1.3-2.0,P<.001)、专科诊疗(aOR 1.5,95%CI 1.10-1.99,P=.0091)、代偿期肝硬化(aOR 2.2,95%CI 1.7-2.8,P<.001)及2011-2021年治疗(aOR 2.3,95%CI 1.8-3.0,P<.001);较年轻者治疗可能性更低(aOR 0.98,95%CI 0.98-0.99,P<.001)。
- 诊断时或之前启动口服抗病毒治疗与生存改善独立相关(aHR 0.84,95%CI 0.72-0.99,P=.037)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although oral antiviral therapy (OAV) is reported to improve outcomes in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), it is underutilized. We determined the rate and factors associated with OAV utilization among patients with HBV-related HCC in a US population with health insurance. METHODS: Patients with HBV-related HCC were identified from the de-identified administrative health claims database for patients with private insurance, Optum Clinformatics (2003-2021). RESULTS: We identified 2129 patients with HBV-related HCC: 71% male, mean age 62.7 ± 12.5 years, 40% Asian individuals, 72% with cirrhosis, and 37% received OAV. The treatment rate improved over time (40.5% after 2010 vs 26.3% earlier; P < .001). Significantly lower treatment rates were noted for females, non-Asian patients, noncirrhotic patients, and patients without gastroenterologist/hepatologist or infectious disease (GI/ID) specialist care (P < .0001). OAV treatment predictors included Asian race and ethnicity (adjusted odds ratio [aOR], 3.6; 95% CI, 2.8-4.5; P < .001), male sex (aOR, 1.6; 95% CI, 1.3-2.0; P < .001), seeing a GI/ID specialist (aOR, 1.5; 95% CI, 1.10-1.99; P = .0091), having compensated cirrhosis (aOR, 2.2; 95% CI, 1.7-2.8; P < .001), and being treated from 2011 to 2021 (aOR, 2.3; 95% CI, 1.8-3.0; P < .001); being younger (aOR, 0.98; 95% CI, 0.98-0.99; P < .001) was less likely for treatment. OAV initiated at or before HCC diagnosis was associated independently with improved survival (adjusted hazard ratio, 0.84; 95% CI, 0.72-0.99; P = .037). CONCLUSIONS: Among patients with HBV-related HCC, only 1 in 3 received OAV despite having insurance coverage. Efforts must continue to develop ways to improve HBV OAV treatment, especially among females, non-Asian patients, and patients without cirrhosis or not seen by specialists.
引用
- Kudaravalli S, Kam LY, Huang DQ, et al. Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study. Clin Gastroenterol Hepatol. 2023. PMID: 37805836. doi:10.1016/j.cgh.2023.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。